BFM
FLNA

Boothbay Fund Management’s Filana Therapeutics FLNA Stock Holding History

Boothbay Fund Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,100
Closed -$24.1K – 1729
2025
Q1 		$24.1K Sell
16,100
-22,500
-58% -$56.8K ﹤0.01% 1324
2024
Q4 		$91.1K Buy
+38,600
New +$678K ﹤0.01% 1300
2021
Q3 		– Sell
-41,300
Closed -$3.53M – 2153
2021
Q2 		$3.53M Buy
+41,300
New +$2.21M 0.11% 205

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Boothbay Fund Management's FLNA Position: Q1 2024 in Review

Boothbay Fund Management sold out of Filana Therapeutics (FLNA) in Q1 2024, closing a stake of 12,000 shares — an estimated $270K sold.

Boothbay Fund Management first reported a position in FLNA in Q2 2019 and held it in 3 quarters. The position peaked at $270K in Q4 2023. 143 funds tracked by Wall St. Rank hold FLNA as of Q1 2024.

  • Boothbay Fund Management reported no remaining Filana Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 12,000 Filana Therapeutics shares in Q1 2024, an estimated $270K.
  • Boothbay Fund Management first reported a position in Filana Therapeutics in Q2 2019 and held it in 3 quarters.
  • Boothbay Fund Management's Filana Therapeutics position peaked at $270K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.